Skull Base Neoplasms

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases and health conditions Scientific studies provide evidence that Embo ASSIST solution can help clinicians reduce patient dose, fluoroscopy time and overall procedure time while performing prostate artery embolization (PAE) CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT. The multi-modality showcase will feature innovations focused on precision care delivery for a wide range of vascular diseases and health conditions. In today’s practice of interventional radiology, clinicians use image guiding technologies to deliver targeted, minimally invasive treatments to help treat a wide range of medical conditions – from cancer care and vascular disease to common health concerns that affect quality of life for both men and women alike. Among the emerging treatments in interventional radiology today, prostatic artery embolization (PAE) has been shown to be an effective treatment for symptomatic benign prostatic hyperplasia (BPH), or an enlarged prostate - the most common prostate condition for men older than age 50.1 The procedure involves targeted release of microscopic particles into the arteries that feed the prostate. The particles stop blood flow into the gland helping to decrease its size and relieve troubling BPH symptoms without any cutting, use of laser or tissue removal. In order for the PAE procedure to be successful, clinicians need to be able to identify the correct arteries and vascular anatomy feeding the prostate in order to deliver precise and targeted treatment. As GE HealthCare continues to advance the Allia IGS platform and interventional innovation, Embo ASSIST AI is the latest addition to the company's ASSIST imaging software. Embo ASSIST AI builds on Embo ASSIST software with AI-based automation designed to automatically segment vascular structures to facilitate embolization workflow planning, as well as help clinicians visualize and anticipate the destination of potential injections. Scientific studies have shown that the use of Embo ASSIST enables users performing PAE to: Reduce patient dose by 44% (Air Kerma) and 58% (Peak Skin Dose);2 Reduce fluoroscopy time by 27% and overall procedure time by 21 minutes (20%);2 Improve anatomy understanding in 46% of cases versus raw cone-beam computed tomography (CBCT), with four times more secondary branches found versus digital subtraction angiography (DSA);3 and Reduce PAE patient dose (DAP) by 70% and improved PAE technical success from 70% without software to 90% with software.4 Embo ASSIST has also been shown to support the development of emerging procedures including rectal artery embolization for hemorrhoidal disease5 as well as intra-arterial chemotherapy infusion in patients with skull base tumors.6 “With GE HealthCare’s Allia IGS platform and innovative solutions like Embo ASSIST, we’re able to bring the best possible care to the patients we serve,” says Dr. Jafar Golzarian of North Star Vascular and Interventional who was part of the first team in the United States to perform a PAE procedure.7 8 “This technology gives us real-time image guidance to deliver precise, targeted and more complete treatments for a wide range of complex diseases and conditions. As an interventionalist who performs a number of different procedures in my daily practice, including PAE, the system is incredibly flexible and provides a number of workflow efficiencies that can be personalized to address my specific needs and preferences around patient positioning and access to help achieve enhanced patient comfort, as well as improved clinical and operational outcomes in my practice.” GE HealthCare designed the Allia IGS Platform to provide workflow efficiency, functionality, and versatility that interventional radiologists require in order to meet the needs of their patients: “As a leader in the interventional space,” said Arnaud Marie – Global General Manager for Image Guiding Solutions at GE HealthCare, “these latest innovations show just what’s possible in the delivery of precision care and demonstrates our commitment to advancing the practice of image guided therapy with artificial intelligence and digitization for clinicians and their patients.” As part of this year’s showcase, GE HealthCare will be exhibiting the following medical devices and digital solutions at SIR 2024 (Booth 520): Image guiding solutions including the Allia IGS platform designed to be a trusted assistant for image guided therapies with features to enhance user experience and improve workflow integration and efficiency; and ASSIST solutions that leverage advanced digitization and AI to help clinicians precisely plan, guide and assess interventional procedures with greater precision and dose efficiency. OEC 3D surgical imaging C-arm provides precise 3D and 2D imaging to surgical suites while enabling efficient imaging every day. Based on GE HealthCare’s proven AW image fabric technology, the OEC 3D C-arm enables clinicians to quickly capture and analyze 2D as well as precise 3D volumetric images with a C-arm, bringing CT-like images into the operating room. CT-Navigation offers clinicians detailed, real-time, 3D CT images for stereotactic needle guidance across an array of care areas, including interventional and oncological procedures as well as biopsies, ablations, drainage, therapeutics and more. LOGIQ E10: Part of the elevated LOGIQ portfolio, LOGIQ E10 includes innovative new features and advanced artificial intelligence (AI) tools designed to address the evolving needs of healthcare providers with easy imaging, efficient workflow and Verisound digital and AI solutions including reporting, fleet management and collaboration tools. LOGIQ E10 also integrates wireless, dual-probe Vscan Air CL—which is well-suited for interventional superficial procedures—for wireless flexibility. GE HealthCare will also be hosting in-booth educational discussions throughout SIR 2024, including: “How to Adapt Advanced Imaging with CBCT Fusion for Vascular Malformation Procedures” with Dr. Michael Miller9 on Sunday, March 24 from 2:30 - 3:00pm MT. “AI Guidance for Prostate Artery Embolization” with Dr. Jafar Golzarian on Monday, March 25 from 12:00 – 1:00pm MT. “Interventional CT: CT guidance assisted by electromagnetic navigation for percutaneous interventions” with Dr. Francois Cornelis10 on Monday, March 25 from 2:30 - 3:00pm. “How Do I Do It: Genicular Artery Embolization” with Dr. Jafar Golzarian on Tuesday, March 26 from 9:45 - 10:45am MT. “Imaging Optimization in Vascular Malformations” with Dr. Michael Miller on Tuesday, March 26 from 2:30 - 3:00pm MT. For more information, visit the GE HealthCare website here. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with 51,000 colleagues working to create a world where healthcare has no limits. Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest news, or visit our website for more information. Barral M, Lassalle L, Gardavaud F, Lehrer R, Haffaf I, Agbonon R, Cussenot O, Cornelis FH. Virtual Injection Software Reduces Radiation Exposure and Procedural Time of Prostatic Artery Embolization Performed with Cone-Beam CT. J Vasc Interv Radiol. 2024 Mar;35(3):409-415. doi: 10.1016/j.jvir.2023.11.012. Epub 2023 Nov 25. PMID: 38008376. This study was supported by a research grant from GE HealthCare. Dr. Barral and Dr. Cornelis consult with GE HealthCare. The statements made by Dr. Cornelis et al are based on his opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital, and many variables exist — e.g., hospital size, case mix, etc. — there can be no guarantee that other customers will achieve the same results. Abstract No. 149 Impact of Cone-Beam CT and Augmented Planning on Complete Prostatic Vascular Anatomy Identification for Prostatic Artery Embolization - Journal of Vascular and Interventional Radiology ( (22)01629-3/fulltext). This study was supported by a research grant from GE HealthCare. Dr. Carnevale consults with GE HealthCare. The statements made by Dr. Carnevale et al are based on his opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital, and many variables exist — e.g., hospital size, case mix, etc. — there can be no guarantee that other customers will achieve the same results. Abstract No. 227 Use of dedicated planning and guidance software results in radiation dose reduction in prostate artery embolization - Journal of Vascular and Interventional Radiology - Journal of Vascular and Interventional Radiology ( (21)00618-7/fulltext). This study was supported by a research grant from GE HealthCare. Dr. McClure consults with GE HealthCare. Raphael Doustaly was a GE HealthCare employee at the time of the study. The statements made by Dr. McClure et al are based on his opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital, and many variables exist — e.g., hospital size, case mix, etc. — there can be no guarantee that other customers will achieve the same results. Rectal Artery Embolization for Hemorrhoidal Disease - Anatomy, Evaluation, and Treatment Techniques ( ) Dr. Vidal consults with GE HealthCare. The statements made by Dr. Vidal et al are based on his opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital, and many variables exist — e.g., hospital size, case mix, etc. — there can be no guarantee that other customers will achieve the same results. Feasibility and Safety of Cone-Beam Computed Tomography Advanced Navigation to Optimize Intra-arterial Chemotherapy Infusion of Skull Base Tumors ( ). This study was supported by a research grant from GE HealthCare. Dr. Cornelis consults with GE HealthCare. The statements made by Dr. Cornelis et al are based on their opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital, and many variables exist — e.g., hospital size, case mix, etc. — there can be no guarantee that other customers will achieve the same results. Paid consultant: Dr. Jafar Golzarian is a paid consultant for GE HealthCare. The statements made by Dr. Golzarian here are based on his own opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital, and many variables exist — e.g., hospital size, case mix, etc. — there can be no guarantee that other customers will achieve the same results. . Paid consultant: Dr. Michael Miller is a paid consultant for GE HealthCare. The statements made by Dr. Miller here are based on his own opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital, and many variables exist — e.g., hospital size, case mix, etc. — there can be no guarantee that other customers will achieve the same results. Paid consultant: Dr. Francois Cornelis is a paid consultant for GE HealthCare. The statements made by Dr. Cornelis here are based on his own opinions and on results that were achieved in his unique setting. Since there is no “typical” hospital, and many variables exist — e.g., hospital size, case mix, etc. — there can be no guarantee that other customers will achieve the same results View source version on businesswire.com: Contacts Emily Niles Global Communications Leader – Image Guided Therapy GE HealthCare +1 262 290 8089 emily.niles@gehealthcare.com Source: GE HealthCare View this news release online at:

Emory University neurosurgeon leads study using NICO's novel biological tissue preservation system INDIANAPOLIS, Aug. 21, 2023 /PRNewswire/ -- Tomas Garzon-Muvdi, MD, MSc, assistant professor of Neurosurgery at Emory University School of Medicine, has been awarded a $75,000 Investigator Initiated Study (IIS) grant from NICO Corporation to evaluate potential increased efficiency of high-throughput organoid formation and cultures for brain tumor biology research and molecular diagnosis using NICO technologies. Organoids are three dimensional tissue cultures that allow researchers to study the complexity and heterogeneity of tumor cells, making them valuable research assets for precision medicine and drug discovery. Continue Reading Dr. Garzon-Muvdi's study, Increasing Efficiency of Organoid Formation and Culture for Brain Tumor Research and Molecular Diagnosis, will use 10 patients with skull base metastases or other primary tumors to compare tissue samples collected through traditional en bloc or dissection methods with samples collected using the patented NICO Myriad and Automated Preservation System (APS). Organoids hold great promise for advancing our understanding of human biology, disease progression and drug discovery. Tweet this "The study is to determine tissue quality using an automated preservation system and the impact it has on our ability to create organoids for molecular research and advanced analyses," said Dr. Garzon-Muvdi. "Automating and standardizing the way brain tissue is collected, maintained, and prepared in a uniform size would save valuable time for lab members working on brain tumor biology research, and it would streamline our work to improve brain tumor patient outcomes." The quality of tissue collected using the NICO Myriad and APS includes critical molecular information that is valuable to researchers and may improve how a patient's brain tumor is treated with various therapies, said Jim Pearson, president and CEO of NICO Corporation. Surgeons typically collect large pieces of tissue and must go through a manual, time consuming disassociation process when tissue is received to prepare it for use in research efforts, such as organoid formation. "Organoids hold great promise for advancing our understanding of human biology, disease progression and drug discovery," Pearson said. "We are hopeful that our technologies can contribute to advancements in science for improved precision medicine therapies. This ultimately impacts the most important factor in this equation, which is the patient with a brain tumor." The NICO Investigator Initiated Study (IIS) grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies. The program supports physicians and researchers across a wide range of neuro-specialties committed to building clinical and scientific data to achieve better outcomes for patients and healthcare providers, as well as expanding the body of evidence for vascular, tumor and oncology clinical practices. Learn more about the IIS program areas of interest and how to apply for a grant. NICO is a pioneer and leader in minimally invasive neurosurgery. It advocates for and supports development of scientific evidence promoting safe and novel approaches to brain disorders and expanding clinical research efforts in pursuit of improved patient outcomes using MIPS. All projects supported by the IIS grant program are conducted by the applicant(s) and their respective affiliate institution(s); NICO is neither involved in collecting information, conducting research, or in the publication of any study project findings. Learn about NICO technologies at NICOneuro.com; follow us on LinkedIn and Twitter, view surgical and patient videos on YouTube. Contact: Sue Goin [email protected] 317.402.8690 SOURCE NICO Corporation

COLUMBUS, Ohio, Feb. 14, 2023 /PRNewswire/ -- Daniel M. Prevedello, MD, MBA, FACS, is being recognized by Continental Who's Who as a Top Pinnacle Professional for his contributions to the medical field. Dr. Prevedello's attended medical school and completed his residency in Brazil. He then completed a fellowship in neuroendocrine and pituitary surgery at the University of Virginia and second fellowship in skull, base, and cerebrovascular surgery at the University of Pittsburgh. In 2010, he joined Ohio State University and became a professor in 2017. According to Dr. Prevedello, he is a well-known neurosurgeon specializing in skull base pathologies and brain tumors. He is the Vice Chair for Academic Affairs & Director of the Skull Base and Pituitary Surgery Programs at the OSUCCC – James, a university research hospital headquartered in Columbus, OH. He remains affiliated with The James Cancer Hospital and Solove Research Institute, Ohio State Same-Day Immediate Care Outpatient Care Worthington, and OSU Wexner Medical Center. He performs skull base surgery for all tumors and diseases of this body area. The doctor explained that neurosurgery is the medical specialty concerned with the prevention, diagnosis, surgical treatment, and rehabilitation of disorders that affect any portion of the nervous system, including the brain, spinal cord, peripheral nerves, and extra-cranial cerebrovascular system. Neurosurgeons are doctors who diagnose and treat problems with the nervous system, often by performing surgery on the brain or spine. They treat strokes, tumors, certain types of congenital disabilities, infections, and head or spinal cord injuries. Dr. Prevedello is considered a pioneer in the endoscopic endonasal approach (EEA) and other minimally invasive techniques for brain tumor removal and is one of only a few neurosurgeons worldwide who have performed more than 1,000 EEA cases. He noted that this technique allows surgeons to access the base of the skull, the intracranial cavity, and the top of the spine by operating through the nose and paranasal sinuses. "Our individualized patient approach, combined with research opportunities, makes The James a very fulfilling place to work. There are few places that offer the types of highly specialized surgery that we do, and I'm proud to be a part of our patients' care," Dr. Prevedello said. His current research focuses on developing minimally invasive approaches to the brain and skull base that will result in the best surgical tumor resection possible with the least amount of disruption to normal tissue. Dr. Prevedello is a Fellow of the American College of Surgeons (FACS) and a member of the Congress of Neurological Surgeons (CNS). He is also board-certified by the Brazilian Society of Neurosurgery (Sociedade Brasileira de Neurocirurgia (SBN)), which is recognized by the World Federation of Neurological Surgeons. The doctor serves as the Executive Director of the North American Skull Base Society, is on the Board of Directors for the Pituitary Network Association, and is active with the tumor sections of the CNS and the American Association of Neurological Surgeons. He has received the Compassionate Doctor Recognition (2016, 2015, 2014, and 2013), the Patients' Choice Award (2016, 2015, and 2013), and the Top 10 Doctor – Neighborhood (2014). Despite his busy schedule, Dr. Prevedello always makes time for his family and to play in a rock and roll band. He enjoys listening to music, and his favorite place to vacation is the Virgin Islands. He speaks English, Spanish, Portuguese, and Italian. Dr. Prevedello would like to thank his mentors Joao Candido Araugo, MD; Edward Laws, MD; and Amin Kassam, MD. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE Continental Who's Who